SF1494 (Legislative Session 94 (2025-2026))
Revision requirement of tests to be administered for determining the presence of a heritable or congenital disorder
Related bill: HF1029
AI Generated Summary
Purpose
This bill requires updating the list of tests used to determine the presence of heritable or congenital disorders. The goal is to keep testing current with advances in medical science and testing methods to protect and improve public health.
Main Provisions
- Periodic revisions: The commissioner must periodically revise the list of tests to be administered for detecting heritable or congenital disorders. Revisions should reflect advances in medical science, new and improved testing methods, or other factors that will improve public health.
- Factors for adding tests: When deciding whether a test must be administered, the commissioner will consider how well the analytical methods can detect the disorder, the ability to treat or prevent conditions caused by the disorder, and how severe the medical conditions are.
- Advisory committee and process: Changes can be made if recommended by the advisory committee established under section 144.1255, approved by the commissioner, and published in the State Register.
- Rulemaking exemption: Revisions are exempt from the usual rulemaking requirements in chapter 14; sections 14.385 and 14.386 do not apply.
- Specific addition: The list of tests must be revised to include metachromatic leukodystrophy (MLD).
Significance and What Changes
- Adds metachromatic leukodystrophy (MLD) to the list of conditions that may be tested for.
- Establishes a formal process for updating the testing list, including committee input, commissioner approval, and publication, while moving updates outside the standard rulemaking process.
How Revisions Work (Key Process)
- Advisory input comes from the advisory committee under section 144.1255.
- The commissioner must approve changes.
- Updated lists must be published in the State Register.
Potential Impacts
- More up-to-date screening capabilities for heritable or congenital disorders.
- Faster integration of new testing methods into practice.
- Possible changes in how families are informed about and access testing, depending on implementation.
Relevant Terms - list of tests to be administered - heritable or congenital disorder - commissioner - periodic revision - advances in medical science - new and improved testing methods - public health - analytical methods - detect the disorder - determine whether a test must be administered - ability to treat or prevent medical conditions - severity of medical conditions - advisory committee (established under section 144.1255) - State Register - rulemaking exemptions - chapter 14 - sections 14.385 and 14.386 do not apply - metachromatic leukodystrophy (MLD) - Minnesota Statutes 2024 section 144.125 subdivision 2 - section 144.1255
Past committee meetings
- Health and Human Services on: March 18, 2025 08:30
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| February 17, 2025 | Senate | Action | Introduction and first reading | ||
| February 17, 2025 | Senate | Action | Referred to | Health and Human Services |
Citations
[
{
"analysis": {
"added": [
"Adds metachromatic leukodystrophy (MLD) to the list of tests to be administered for determining the presence of a heritable or congenital disorder.",
"Requires periodic revision of the list to reflect advances in medical science and testing methods.",
"Revisions must be recommended by the advisory committee established under section 144.1255, approved by the commissioner, and published in the State Register.",
"The revision is exempt from the rulemaking requirements in chapter 14, and sections 14.385 and 14.386 do not apply."
],
"removed": [],
"summary": "This bill amends Minnesota Statutes 2024 section 144.125, subdivision 2, to revise the list of tests to determine the presence of a heritable or congenital disorder and to add metachromatic leukodystrophy (MLD). It also establishes that revisions may occur periodically based on advances in medical science, must be recommended by the advisory committee established under section 144.1255, approved by the commissioner, and published in the State Register; revisions are exempt from the rulemaking requirements in chapter 14, and sections 14.385 and 14.386 do not apply.",
"modified": [
"Revises the process for determining and updating the list of tests to include new testing methods and to reflect advances in science.",
"Links the revision process to the advisory committee under section 144.1255."
]
},
"citation": "144.125",
"subdivision": "subd. 2"
},
{
"analysis": {
"added": [
"Explicitly ties revisions to recommendations from the advisory committee established under section 144.1255."
],
"removed": [],
"summary": "The bill references the advisory committee established under section 144.1255 as the body that must recommend revisions to the list of tests under 144.1252.",
"modified": [
"The revision process described in 144.1252 relies on the advisory committee established under 144.1255."
]
},
"citation": "144.1255",
"subdivision": ""
},
{
"analysis": {
"added": [
"Exemption from the rulemaking requirements in sections 14.385."
],
"removed": [],
"summary": "The bill states that the revisions to the list are exempt from the provisions of sections 14.385.",
"modified": []
},
"citation": "14.385",
"subdivision": ""
},
{
"analysis": {
"added": [
"Exemption from the rulemaking requirements in sections 14.386."
],
"removed": [],
"summary": "The bill states that the revisions to the list are exempt from the provisions of sections 14.386.",
"modified": []
},
"citation": "14.386",
"subdivision": ""
}
]Progress through the legislative process
In Committee